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ABSTRACT 
Objective: The aim of this study was to develop a solid dosage form of glibenclamide with increasing the solubility properties of glibenclamide with 
cocrystallization method. 
Methods: Virtual screening was performed to investigate the interaction between glibenclamide and a co-former. Saccharin, the selected co-former, 
then co-crystallized with glibenclamide with equimolar ratios of 1:1 and 1:2 using the solvent evaporation method. Further characterization was 
performed using an infra-red (IR) spectrophotometer, differential scanning calorimetry (DSC), and powder x-ray diffraction (PXRD). 
Results: Co-crystals of 1:2 equimolar ratio were more highly soluble compared to pure glibenclamide (30-fold for 12 h and 24-fold for 24 h). The 
dissolution rate had also increased from 46.838% of pure glibenclamide to 77.655% of glibenclamide co-crystal in 60 min. There was no chemical 
reaction observed during the co-crystallization process based on the IR spectrum. However, there was a new peak in the X-Ray diffractogram and a 
reduction of melting point in the DSC curve, indicating the formation of co-crystals. 
Conclusion: The optimal co-crystal ratio of glibenclamide-saccharin was found to be 1:2, which was successful in improving the solubility of 
glibenclamide. 
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Oral preparation is the easiest and most widely used drug delivery 
route because it has several advantages, namely ease of 
administration, high level of patient compliance, cost-effective, and 
tends to be flexible in terms of dosage formulations. However, the 
biggest challenge in designing oral dosage form is low bioavailability 
property. Bioavailability is influenced by several factors, including 
water solubility, drug permeability, dissolution rate, first-pass 
metabolism, and pre-systemic metabolism. The most common causes 
of low bioavailability are low solubility and permeability [1, 2]. 
Today, nearly 40% of pharmaceutical preparations on the market 
have low solubility based on the biopharmaceutical classification 
system (BCS). It is estimated that 90% of drugs that currently being 
developed are classified to poor-soluble drugs [3]. In the past, the 
industry consensus thought that those candidates was highly risk in 
drug development. However, because of the large number of them, 
the industry consensus also changed the point of view of the drugs 
from avoidance to acceptance as the dedication of the research 
provided to solve the challenges regarding the solubility [4, 5]. 
In dealing with this problem, the pharmaceutical industry has 
developed several methods to improve drug solubility. These 
methods include salt formation [6], co-crystal [7], self-emulsifying 
drug delivery systems (SEEDS) [8], cyclodextrin [9], pH-micro-
environmental modifiers [10], solid lipid nanoparticles [11], micelles 
[12], high energy polymorphs [13], soft gelatin capsules [14], and 
liposomes [15]. Co-crystallization method and salt formation have 
several advantages in physicochemical properties and are able to 
improve the parent drug without changing therapeutic efficiency [7]. 
Traditionally, the formation of salt is more widely used by 
researchers in the medicinal and synthetic chemistry field by using 
bases or weak acids [6]. However, only 20-30% of the new 
molecules can form salt spontaneously, so that 70-80% of the 
remaining molecules must be given via different routes to increase 
solubility [16]. Another simple method to improve solubility is co-
crystallization. Co-crystallization method is a method of co-crystal 
formation by adding co-former into active pharmaceutical 
ingredients in order to increase solubility without affecting its 
pharmacological activity [17]. Formation of co-crystal is better in 
reducing unintended property of the parent substance [18]. 
The previous study showed that co-crystallization method can 
increase the solubility of simvastatin 2-fold from pure simvastatin 
with malic acid as the co-former [19]. Bencoic acid and aspartam 
also could be used as co-former in improving atorvastatin solubility 
by the co-crystallization method, from 22.08 ppm to 28.91 ppm and 
30.20 ppm, respectively [20]. In this study, the co-crystal of 
glibenclamide-saccharin were prepared with the equimolar ratio is 
1:1 and 1:2. Saccharin is the excipient that easily accessible and has 
an affordable price. As a co-former, saccharin could increase 
ketoprofen solubility up to 30% [21]. 
MATERIALS AND METHODS 
Materials  
Glibenclamide was obtained from PT. Indofarma Tbk, Bekasi, 
Indonesia. Saccharin, methanol, potassium dihydrogen phosphate, 
and potassium hydrogen phosphate were purchased from Merck, 
Germany. All reagents used were analytical grade.  
Methods 
Virtual screening 
The virtual screening method was used to predict the bond formed 
between glibenclamide and its co-former. The expected bonds were 
hydrogen, van der Waals, and π-π bonds. The 2D structure of the 
active pharmaceutical ingredients and co-former was prepared 
using ChemBioDraw Ultra 12.0 (trial version) and converted into. 
cdx format. The 2D structure was converted into a 3D structure 
using ChemBio3D Ultra 12.0 (trial version) by the mechanical 
method (Hartree-Fock, set 321G), and the file was saved as a. pdb 
format. Molecular docking of active pharmaceutical ingredients was 
performed using PyRx-Virtual Screening Tools (trial version) with 
AutoDock Vina as the engine. The molecular docking results were 
analyzed based on binding affinity value, type, and the position of 
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bonds formed between glibenclamide and the co-former using 
AutoDock Tools-1.5.6rc3 (trial version) [22].  
Preparation of glibenclamide co-crystal using solvent 
evaporation method 
Glibenclamide and saccharin were weighed in accordance with 
equimolar ratios of 1:1 and 1:2. Each mixture was dissolved in 
methanol homogenously and evaporated in a water bath at 45 °C for 
24 h or until the methanol completely evaporated. The co-crystal 
obtained was stored in a desiccator and further analyzed for 
characterization and evaluation [22]. 
Optimization of pH of glibenclamide dissolution medium  
Buffer phosphate solution (BPS) was used as the dissolution 
medium and prepared with various pH (6.4; 7.6; 8.0) for 900 ml. 
Dissolution test of standard glibenclamide was performed using 
type 2 apparatus (paddle) at 75 rpm for 60 min (37 ±0.2 °C). At 
predetermined interval times (5; 10; 15; 30; 45; 60 min), 5 ml of 
sample was taken and then replaced by fresh medium. The aliquot 
sample was analyzed using a UV Spectrophotometer (analytical Jena, 
specord 200®) to quantify the amount of dissolved glibenclamide 
concentration and the optimum pH of the medium [23]. 
Determination of solubility  
Each co-crystal of glibenclamide was weighed equivalently to 20 mg 
glibenclamide then put into 20 ml distilled water and shaken for 12 
and 24 h using a mechanical agitator (IKA HS 260 basic®)at 120 rpm 
at room temperature. After shaking, the solution was filtered and 
diluted into 100 ppm using methanol. Each sample was analyzed using 
a UV-Vis Spectrophotometer (analytical Jena, specord 200®) [24]. 
Dissolution test 
Dissolution test of glibenclamide was performed using type 2 
apparatus (paddle) at 75 rpm for 60 min (37 ±0.2 °C). The medium 
was BPS (pH 8.0) 900 ml. At predetermined interval times (5; 10; 
15; 30; 45; 60 min), 5 ml of sample was taken and then equally 
replaced by fresh medium. The aliquot sample was analyzed using a 
UV Spectrophotometer (analytical Jena, specord 200®) to quantify 
the amount of dissolved glibenclamide concentration [23]. 
Characterization 
Infrared spectrophotometry 
1 mg of Co-crystal of glibenclamide was carefully weighed and 
homogeneously mixed with 250 mg of KBr. The mixture was 
compressed at 80 Psi to obtain a pellet. The pellet was analyzed 
using an infrared spectrophotometer (Shimadzu®) at room 
temperature in a range of wavenumbers from 400-4000 cm-1
Powder X-ray diffraction (PXRD) 
. The 
KBr pellet was used as a blank [25]. 
PXRD measurements were conducted using Phillip PW 1835 under 
the following conditions: target, Cu; voltage, 40 kV; and current, 
40mA. The scans were performed with a detector step size of 0.02 ° 
over an angular range of 2θ = 2-50 °C [26]. 
Differential scanning calorimetry (DSC) 
DSC analysis was performed usingLinseis DSC PT1000, which was 
periodically calibrated using indium. Approximately 4 mg of the 
powder sample was placed in an aluminum pan with a pinhole for 
the measurement. Dry nitrogen was used as the inert gas at a flow 
rate of 30 ml/min, and the measurements were carried out at 50-
300 °C at a heating rate of 10 °C/min [26]. 
RESULTS AND DISCUSSION 
Virtual screnning of glibenclamide co-crystal 
Virtual screening was performed using molecular modelling and the 
molecular docking program to predict the bonds formed when 
combining glibenclamide and the co-former structure. Virtual 
screening was used to determine which co-former should be used in 
later steps [27]. Molecular docking was used to determine that the 
selected parameter of the co-former had a high number of hydrogen 
bonds and a small value of energy of interaction (Ei); the smaller the 
Ei, the stronger the bond [20]. 
 
Table 1: The result of the virtual screening of glibenclamide-saccharin 








The virtual screening results showed that two interactions were 
observed. Hydrogen bonds were formed from hydrogen atoms of the 
amide groups of glibenclamide and oxygen atoms of sulfonyl of 
saccharin (table 1). In addition, π-π and van der Waals bonds could 
also be used as a selection parameter of the co-former. However, π-π 
bonds have lower electronegativity than hydrogen bonds, and van 
der Waals bonds are weaker than hydrogen bonds [28, 21]. Covalent 
bonds are undesirable because they are immensely strong, will bind 
irreversibly to the body, and may cause toxicity [29]. 
Preparation of glibenclamide co-crystal 
Slow solvent evaporation and grinding are widely used co-
crystallization methods, thus the common principles in the co-
crystallization process were solvent-based and grinding. Therefore, 
the co-crystallization process of glibenclamide-saccharin was 
performed using the basic solvent evaporation method, as the 
objective was to attain solubilization and slow evaporation. While 
the solvent evaporated, the molecules in the solution reacted and 
formed hydrogen bonds. Thus, an advantage of this method was that 
the optimal co-crystal obtained might improve the solubility of the 
active pharmaceutical ingredient [30]. Co-crystallization using the 
equimolar ratio of each component was appropriate in the solvent 
evaporation method because, with the stoichiometry ratio, the 
possibility of generating intermolecular bonds is high [31]. 
Determination of solubility 
In this study, the determination of solubility of the glibenclamide co-
crystal was performed based on the Higuchi and Connor method, 
which consists of five steps to determining the solubility of a 
compound: sample preparation, equilibration, separation, sample 
analysis, and data analysis [24]. 
The solubility of glibenclamide-saccharin (1:2) was higher than the 
solubility of its pure form and glibenclamide-saccharin (1:1) (fig. 1). 
The higher content of the co-former led to the improvement of 
solubility because the co-former can reduce barriers of the 
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compound, thus making the solubilization process easier [32]. In 
this study, saccharin as a co-former was capable of reducing the 
barrier because it was highly soluble in water and then ionized; thus, 
the drug was solubilized easier [33]. 
  
 
Fig. 1: Solubility of glibenclamide co-crystal for 12 and 24 h (All the values were calculated as mean±standard deviation; n=3) 
 
Dissolution test 
The dissolution test was performed on the co-crystal with the best 
equimolar ratio based on the solubility test i.e., glibenclamide-
saccharin 1:2 compared with pure glibenclamide. Optimization of 
pH of dissolution medium was performed at pH 6.4, 7.6, and 8.0. In 
table 4, the concentration of standard glibenclamide 60 min was 
9.91, 16.43, and 45.31 ppm for pH 6.4, 7.6, and 8.0, respectively. 




Fig. 2: Optimization of pH of dissolution medium (All the values were calculated as mean±standard deviation; n=3) 
 
In fig. 2, the dissolution rate of co-crystal of glibenclamide-
saccharin was higher than its pure form. As stated in the literature, 
glibenclamideonly dissolved 45% in 60 min. In this study, pure 
glibenclamide dissolved 46.83% in 60 min [34]. However, the co-




Fig. 3: Result of dissolution test of pure glibenclamide (blue line) and glibenclamide-saccharin (red line) (All the values were calculated as 
mean±standard deviation; n=3) 
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Characterization 
Characterization of the co-crystal was performed on glibenclamide-
saccharin (1:2) and its pure form. The aim of characterization was to 
determine the characteristics of the co-crystal and compare it with 
pure glibenclamide. 
Infrared spectrophotometry 
In fig. 3, the peaks of pure glibenclamide were 33367.71 cm-1and 
3313.71 cm-1 (N-H Stretch), 3116.97 cm-1 (O-H Stretch), 2931.80 cm-1, 
and 2854.65 cm-1 (C-H Stretch), 1716.65 cm-1 (C=O Stretch) and 1616.35 
cm-1 (C=C Stretch). The peaks of pure saccharin were 3398.57 cm-1(N-H 
Stretch), 3093.82 cm-1 (O-H Stretch), 2974.23 cm-1 (C-H Stretch) and 
1724.3665 cm-1 (C=O Stretch). The peaks of the co-crystal of 
glibenclamide-saccharin were 3367.71 cm-1and 3313.71 cm-1 (N-H 
Stretch), 3093.82 cm-1 (O-H Stretch), 2931.80 cm-1and 2854,65 cm-1 (C-H 
Stretch), 1616.35 cm-1 (C=C Stretch) and 1720.50 cm-1 (C=O Stretch). The 
C=O peak was weakened from 1716.65 cm-1 to 1720.50 cm-1, indicating 
that there was a formation of hydrogen bonds marked by a bond on the 
extended of C=O group, which reduced the bond strength. Compared to 
the functional group of glibenclamide-saccharin and its components 
(glibenclamide and saccharin), no new peaks were observed, indicating 
that no additional functional group was formed and no chemical reaction 
occurred during co-crystal preparation. However, the peaks of 2009.83 
cm-1, 1975.11 cm-1, and 1863.24 cm-1
 
 in the glibenclamide-saccharin 
spectrum were from the saccharin peaks. 
 
Fig. 4: Infrared spectrum of pure glibenclamide (black line), saccharin (blue line), and glibenclamide-saccharin (red line) 
 
Powder X-ray diffraction (PXRD) 
In fig. 4, the intensity of the glibenclamide-saccharin (1:2) 
diffractogram was higher than glibenclamide and saccharin. Pure 
glibenclamide was semi-crystalline, but both saccharin and 
glibenclamide-saccharin were crystalline. The highest intensity of 
glibenclamide-saccharin (1:2) was 100% at 2θ of 15.79 °. Peak 
amounts of pure glibenclamide and glibenclamide-saccharin were 
different, at 40 and 44 peaks, respectively.  
These differences indicate that there was a difference in the structure 
due to the co-crystal formation [35, 36]. 
 
 
Fig. 5: Diffraction of glibenclamide (a), saccharain (b), and glibenclamide-saccharin (1:2) (c) 
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Table 2: The result of PXRD 
2θ ( °) Intensity 
Glibenclamide Saccharin  Glibenclamide-saccharin (1:2) 
15.79 11.30 10.68 100 
24.93 10 44 83.02 
 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) is an analytical instrument used 
in characterization to determine the solid-state interaction of two 
compounds or more by giving heat energy to the co-crystals to evaluate 
thermodynamic changes (endothermic or exothermic peaks) [37]. 
Changes were noted in the thermodynamic aspects of the solid as well as 
in the shape of the solid crystalline structure due to the physical 
interaction by the thermal analysis of two compounds or more [25]. 
The thermogram of glibenclamide, saccharin, and glibenclamide-
saccharin can be seen in fig. 5 and table 6. In the thermogram, there 
was an endotherm peak of pure glibenclamide at 174.66 °C, 
indicating the melting point of glibenclamide, and 259.89 °C, 
indicating the decomposition of glibenclamide. The endotherm peak 
of saccharin was at 229.06 °C, indicating that saccharin did not have 
a melting point but started to degrade after reaching said 
temperature. The glibenclamide-saccharin melting point was lower 
than those of glibenclamide and saccharin alone, at 157.87 °C. 
Compared to solubility properties, it is reasonable to conclude that 
glibenclamide-saccharin has a higher solubility than pure 
glibenclamide. According to the literature, the co-crystallization 
process results in a change of the melting point of the compound 
compared to its components, as a co-crystal melting point is 
typically lower than those of its components [22, 37]. 
 
Table 5: The result of DSC analysis 
Sample Melting point ( °C) 
Onset Peak Endset 
Glibenclamide 171.96 174.66 178.33 
Saccharin 225.65 229.06 233.61 
Glibenclamide-saccharin 145.60 157.87 170.69 
 
 
Fig. 6: DSC thermogram of (a) glibenclamide, (b) saccharin, and (c) glibenclamide-saccharin (1:2) 
 
CONCLUSION 
The co-crystallization method was successful in improving the 
solubility of glibenclamide using saccharin as the co-former with an 
optimal equimolar ratio of 1:2. The dissolution rate also increased 
from 46.838% of pure glibenclamide to 77.655% of glibenclamide 
co-crystal in 60 min. There was no chemical interaction observed 
based on the infrared spectrum, but the co-crystal was successfully 
formed based on the diffractogram and thermogram. 
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